What if the solution for a chronic disease lies in our ocean, rivers, or lakes? The EU-funded Algae4IBD project will answer this question. Studying compounds from marine and freshwater micro and macroalgae (seaweed) from lab/pilot to market scale, the project will comprehensively research means to transform aquatic natural biological resources into biologically active compounds for the prevention and treatment of inflammatory bowel disease (IBD). Specifically, it will develop algae-based compounds while ensuring algae biodiversity preservation through pioneering cultivation and extraction technologies. Algae4IBD proposes innovative solutions to sustainably use algae-based products with improved nutritional quality to positively impact IBD patients.
ENCO is the leader of WP7 LCS and business exploitation and it is responsible for IPR Management.